Sander Bins

Sander Bins is a researcher in the Department of Medical Oncology at Erasmus MC, a leading academic medical center in the Netherlands. His work is centered on clinical pharmacology and personalized cancer therapy, with a focus on pharmacogenetics and immune checkpoint inhibitors.

His research interests lie at the intersection of oncology and pharmacology, particularly in understanding how genetic variations influence drug response and toxicity in cancer patients. Key areas include pharmacogenetics of chemotherapeutic agents such as irinotecan and capecitabine, adverse events associated with immune checkpoint inhibitors, and thromboembolic complications in melanoma. His studies often involve cohort analyses and systematic reviews to identify genetic and clinical predictors of treatment outcomes.

The trends in his recent publications indicate a strong emphasis on personalized medicine, using genetic markers like UGT1A1, DPYD, and ABCG2 to predict toxicity, and exploring pharmacokinetic factors that affect drug safety. His work bridges translational research and clinical application, aiming to improve patient stratification and reduce adverse events in oncology.

He has contributed to influential review articles and original research in high-impact journals such as Cancer Treatment Reviews and Clinical Pharmacokinetics. His research has been cited in patents and widely read on platforms like Mendeley, indicating significant academic impact.

Sander Bins has supervised at least three research projects, indicating active involvement in mentoring junior scientists and contributing to academic training. While no formal grants are mentioned, his participation in multi-center studies suggests collaboration within funded research programs.

He is affiliated with the Medical Oncology department at Erasmus MC, which is part of the Faculty of Medicine. The department is known for its cutting-edge research in cancer therapeutics, pharmacology, and translational medicine.